{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=59", "query": { "intervention": "Injectable Placebo", "page": 59 }, "page_size": 10 }, "pagination": { "page": 59, "page_size": 10, "total_count": 4216, "total_pages": 422, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=60&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=58&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T10:03:44.965Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04232657", "title": "Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Spinal Cord Injury (=3 Years)", "Sublesional Bone Loss Secondary to SCI" ], "interventions": [ { "name": "Romosozumab", "type": "DRUG" }, { "name": "Denosumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 36, "start_date": "2021-03-01", "completion_date": "2026-08-24", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-27T10:03:44.965Z", "location_count": 2, "location_summary": "West Orange, New Jersey • The Bronx, New York", "locations": [ { "city": "West Orange", "state": "New Jersey" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04232657" }, { "nct_id": "NCT00983853", "title": "Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C", "HIV Infections" ], "interventions": [ { "name": "telaprevir or matching placebo", "type": "DRUG" }, { "name": "peginterferon alfa-2a", "type": "BIOLOGICAL" }, { "name": "ribavirin (fixed dose)", "type": "DRUG" }, { "name": "ribavirin (weight-based dose)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 62, "start_date": "2009-10", "completion_date": null, "has_results": true, "last_update_posted_date": "2013-10-10", "last_synced_at": "2026-10-27T10:03:44.965Z", "location_count": 11, "location_summary": "Beverly Hills, California • San Diego, California • San Francisco, California + 8 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00983853" }, { "nct_id": "NCT00976937", "title": "24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Lixisenatide Placebo", "type": "DRUG" }, { "name": "Pen auto-injector", "type": "DEVICE" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Sitagliptin Placebo", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 319, "start_date": "2009-08", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2016-10-11", "last_synced_at": "2026-10-27T10:03:44.965Z", "location_count": 21, "location_summary": "Montgomery, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 17 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Paramount", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00976937" }, { "nct_id": "NCT04779645", "title": "Effects of GRA in Patients With Type 1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 1 Diabetes" ], "interventions": [ { "name": "REMD-477", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2021-07-31", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2025-06-10", "last_synced_at": "2026-10-27T10:03:44.965Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04779645" }, { "nct_id": "NCT01673672", "title": "CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Moderate to Severe Allergic Asthma" ], "interventions": [ { "name": "CYT003", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Cytos Biotechnology AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 365, "start_date": "2012-11", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2014-05-14", "last_synced_at": "2026-10-27T10:03:44.965Z", "location_count": 21, "location_summary": "Los Angeles, Huntington Beach, San Jose, California • Walnut Creek, San Diego, Riverside, Fountain Valley, California • Colorado Springs, Denver, Colorado + 18 more", "locations": [ { "city": "Los Angeles, Huntington Beach, San Jose", "state": "California" }, { "city": "Walnut Creek, San Diego, Riverside, Fountain Valley", "state": "California" }, { "city": "Colorado Springs, Denver", "state": "Colorado" }, { "city": "Waterbury", "state": "Connecticut" }, { "city": "Miami, Tallahassee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01673672" }, { "nct_id": "NCT00447265", "title": "Etanercept for the Treatment of Lupus Nephritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lupus Nephritis" ], "interventions": [ { "name": "Etanercept", "type": "DRUG" }, { "name": "Lupus Treatment- Standard of Care", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1, "start_date": "2008-02", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2013-02-12", "last_synced_at": "2026-10-27T10:03:44.965Z", "location_count": 6, "location_summary": "Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Manhasset", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00447265" }, { "nct_id": "NCT05606757", "title": "A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ventral Hernia", "Abdominal Hernia" ], "interventions": [ { "name": "BOTOX Dose A", "type": "DRUG" }, { "name": "Placebo for BOTOX", "type": "DRUG" }, { "name": "BOTOX Dose B", "type": "DRUG" }, { "name": "BOTOX Dose C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 0, "start_date": "2024-05-07", "completion_date": "2025-09-26", "has_results": false, "last_update_posted_date": "2024-05-16", "last_synced_at": "2026-10-27T10:03:44.965Z", "location_count": 2, "location_summary": "Mineola, New York • Charlotte, North Carolina", "locations": [ { "city": "Mineola", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05606757" }, { "nct_id": "NCT07893457", "title": "Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Obese Adults" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Tirzepatide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 30, "start_date": "2026-10-26", "completion_date": "2027-10-26", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-10-27T10:03:44.965Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07893457" }, { "nct_id": "NCT05614544", "title": "Dose-Finding and Human Abuse Potential Study Of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "General Anesthesia" ], "interventions": [ { "name": "HSK3486", "type": "DRUG" }, { "name": "Propofol", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Haisco-USA Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 42, "start_date": "2022-08-16", "completion_date": "2023-10-03", "has_results": false, "last_update_posted_date": "2023-10-13", "last_synced_at": "2026-10-27T10:03:44.965Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05614544" }, { "nct_id": "NCT07219771", "title": "A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Knee Osteoarthritis" ], "interventions": [ { "name": "PTP-01", "type": "BIOLOGICAL" }, { "name": "Placebo control / saline vehicle", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Doron Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 300, "start_date": "2025-10-14", "completion_date": "2027-12-30", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-27T10:03:44.965Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Tucson, Arizona • La Mesa, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Mesa", "state": "California" }, { "city": "West Hills", "state": "California" }, { "city": "Winter Park", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07219771" } ] }